Revvity, Inc. (RVTY)

Life sciences reagents, instruments and diagnostics, 80% abroad. Read October 19, 2026 from the annual report for the period ending December 28, 2025, filed February 24, 2026. Ranked 43 of the 95 Healthcare companies read so far, by the share within reach now.

Revvity states approximately 11,000 employees at December 28, 2025, roughly 80% outside the United States, 2,000 of them sales and service representatives, across Life Sciences and Diagnostics segments of equal revenue with no count by kind of work, so the reagents and diagnostic kits, the instruments and the laboratory services are split by description (c).

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 20% now, 36% at the end of 2027, 44% at the end of 2028, 48% at the end of 2030. By the patterns, the work is about 48% desk work, 16% people work and 36% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 53% of the working time stays with people (conversation, in-person and hands-on work), 39% becomes checking a model's work and 5% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

11,000 employees as of December 28, 2025 (stated). The filing states that roughly 80% of the workforce is based outside of the United States (about 20% in the U.S.).

The filing: “Human Capital Management As of December 28, 2025, we employed approximately 11,000 employees on a worldwide basis.”

The workforce as industry patterns

What the filing says about the workforce: Approximately 2,000 sales and service representatives in about 40 countries; labor union and works council agreements involve approximately 4,000 employees (36%) at subsidiaries outside the United States; roughly 80% of the workforce outside the U.S.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Johnson & Johnson (JNJ, 140,800 employees)19% now, 39% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)20% now, 49% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)19% now, 41% by 2028
• Pfizer Inc. (PFE, 75,000 employees)19% now, 41% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)19% now, 41% by 2028
• Eli Lilly and Company (LLY, 50,000 employees)19% now, 41% by 2028
• Bristol-Myers Squibb Company (BMY, 32,500 employees)19% now, 41% by 2028
• Amgen Inc. (AMGN, 31,500 employees)19% now, 41% by 2028

What the filing says about AI

15 sentences in the filing name AI. The filing names AI in its software: Phenologic.AI deep-learning image analysis, Nuclei AI nucleus detection and the Living Image Synergy AI imaging platform, among its product innovations.

• “Our strategy includes: Strengthening our position within key markets by expanding our global product and service offerings, maintaining superior product quality and driving an enhanced customer experience; Attracting, retaining and developing talented and engaged employees; Accelerating transformational innovation through both internal research and development and third-party collaborations and...”
• “Software ◦ Phenologic.AI™ software, a module in our Harmony™ high-content imaging and analysis software and in our Signals Image Artist™ image analysis and data management platform, uses a pre-trained deep-learning image-analysis model to enable analysis of brightfield images and provides an additional channel for multiplexing and easier analysis of live cell assays.”
• “Its Nuclei AI building block enables reliable nucleus detection without staining, eliminating manual tuning and accelerating image analysis with greater precision. ◦ The Living Image™ Synergy AI in vivo imaging software platform enables acquisition, visualization, and quantitative analysis across optical, microCT, ultrasound, and multimodal workflows.”
• “The platform enables scientists to manage data across the complete design-make-test-analyze cycle and leverage structured data to support AI-driven decision-making. ◦ Luminata ® enterprise decision-support software that consolidates analytical and chemical data for pharmaceutical and chemical product development.”
• “Technology and Licensing ◦ The Pin-point ® base editing platform was expanded to include AI-enhanced adenine deaminase editors in collaboration with Profluent, providing a toolkit for therapeutic applications where control, safety, and reproducibility are paramount. ◦ The HostDetect™ PCR DNA quant kits detect host cell contamination throughout bioprocessing workflows. 8 Table of Contents Brand...”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20220median 0
• Fiscal 20230median 1
• Fiscal 20243median 4
• Fiscal 202515median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• No count by kind of work beyond the sales force: the three shares are by description (c).

Source: the company's annual report on EDGAR, accession 0000031791-26-000012, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.